Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review

Sarbajit Mukherjee; Kanak Parmar; Elizabeth Smyth

doi:10.1177/17588359221139625

Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review

Ther Adv Med Oncol. 2022 Nov 29:14:17588359221139625. doi: 10.1177/17588359221139625. eCollection 2022.

Authors

Sarbajit Mukherjee¹, Kanak Parmar², Elizabeth Smyth³

Affiliations

¹ Department of Medicine - GI Medical Oncology, Roswell Park Comprehensive Cancer Center, Scott Bieler Clinical Science Center, 9th Floor P-934, Elm & Carlton Streets, Buffalo, NY 14263, USA.
² Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
³ Department of Oncology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.

Abstract

Gastroesophageal cancers (GEC) have a poor survival rate of 20-30% at 5 years, often due to delayed presentations. Neoadjuvant chemoradiotherapy (CRT) followed by surgery or peri-operative chemotherapy and surgery are widely used as the standard of care for patients with resectable GEC. Immune checkpoint inhibitors (ICIs) have improved survival in metastatic and recurrent GEC which led to their application in resectable GEC. Based on the pivotal CheckMate 577 study results, the Food and Drug Administration (FDA) approved nivolumab for patients with completely resected high-risk esophageal or gastroesophageal junction cancer (GEJC). Several ongoing trials with many ICIs could potentially improve resectable GEC outcomes. This review explores the rationale for using ICIs in resectable GEC and discusses the significance of reported clinical trials. Finally, we will examine some ongoing clinical trials and the challenges as well as prospects of ICIs in resectable GEC.

Keywords: adjuvant; esophageal cancer; gastric cancer; immunotherapy; neo-adjuvant; nivolumab; pembrolizumab; peri-operative; resectable.

Publication types

Review